Market Size of Global Virology Testing Industry
Study Period | 2019 - 2029 |
Market Size (2024) | USD 13.02 Billion |
Market Size (2029) | USD 14.21 Billion |
CAGR (2024 - 2029) | 1.77 % |
Fastest Growing Market | Asia-Pacific |
Largest Market | North America |
Major Players*Disclaimer: Major Players sorted in no particular order |
Need a report that reflects how COVID-19 has impacted this market and its growth?
Virology Testing Market Analysis
The Global Virology Testing Market size is estimated at USD 13.02 billion in 2024, and is expected to reach USD 14.21 billion by 2029, growing at a CAGR of 1.77% during the forecast period (2024-2029).
Amidst COVID-19, the virology testing market is expected to grow owing to the rising cases of COVID-19 among people and the advent of newer COVID-19 viral strains across the globe. The impact of COVID-19 was significant as several companies launched their tests for the virus, and there was a need for the diagnosis of SARS-CoV-2 virus-infected patients and screening of people, which created lucrative opportunities for the virology testing market. According to the World Health Organization (WHO), in 2022, the number of new COVID-19 cases increased by 5% across the globe. The market players took this opportunity to expand their product lines and gain a significant market share by providing diagnostic tests and kits. As per an article titled "At clinical virology lab, 1 million COVID-19 tests and counting" published in February 2022, Stanford Medicine processed its 1 millionth COVID-19 PCR test in February 2022. To contain an unidentified, rapidly developing global health crisis, Stanford Medicine was one of the first academic medical centers in the United States to receive emergency use authorization from the Food and Drug Administration for its coronavirus PCR test. Moreover, increasing initiatives undertaken by various public and private organizations to maximize product supply and output will further drive the market's growth. For instance, in September 2021, the United States government signed an agreement to spend USD 626 million on Celltrion Healthcare (South Korea) and USD 554.4 million on Abbott Laboratories (United States) to purchase rapid COVID-19 tests for nursing homes and other high-risk populations as part of President Joe Biden's vaccinate or test plan. Such collaborations between industry players and government bodies are anticipated to greatly benefit manufacturers across the globe, thereby accelerating market growth. Such instances are likely to have a positive impact on the market's growth over the pandemic phase.
Furthermore, the increasing prevalence of viral diseases, the emergence of new pathogens, and a surge in the number of product approvals are expected to be the major driving factors over the coming years. For instance, according to the World Health Organization (WHO), in 2021, 60% of the global population was suffering from infectious diseases. The rising incidence of viral diseases such as human immunodeficiency virus (HIV), influenza, Ebola, Zika virus, and other sexually transmitted diseases has led to an increasing demand for virology testing for an effective diagnosis of the infections. According to the World Health Organization (WHO), in 2021, since the beginning of the epidemic, 79.3 million people have been infected with the human immunodeficiency virus (HIV) and 36.3 million people have died of HIV. Similarly, the report published by the Food and Agriculture Organization (FAO) in January 2022 stated that 13 new cases of the avian influenza virus occurred in China while 5 cases occurred in the United Kingdom.
Additionally, the World Health Organization (WHO) in 2021 reported that 3,481 cases of Ebola were present in the world. The organization further stated that more than 1 million sexually transmitted infections (STIs) were still being acquired every day prior to the pandemic, and every year, more than 350,000 babies were born with severe outcomes, including 200,000 stillbirths and new-born deaths linked to STIs.
Therefore, the increasing prevalence of such diseases and the emergence of new viral infections are anticipated to drive the demand for virology testing kits and instruments, in turn, bolstering the growth of the virology testing market. On the other hand, stringent regulations regarding product approvals are likely to hamper the market's growth over the forecast period.
Virology Testing Industry Segmentation
As per the scope of the report, virology testing involves different diagnostic techniques used in identifying viruses. Viruses can be diagnosed by different procedures such as cell culture methods, specific antibody detection, antigen detection, virus nucleic acid detection, gene sequencing, and hemagglutination assays. The Virology Testing Market is segmented By Type (Instruments, Assay Kits and Consumables), By Diagnostic Technique (Molecular Diagnostics Method, Immunoassay based Method, Mass Spectroscopy based Method, and Others), By End User (Hospitals and Clinics, Diagnostic Laboratories, and Others) and Geography (North America, Europe, Asia-Pacific, Middle East & Africa, and South America). The report offers value (in USD million) for the above segments. The market report also covers the estimated market sizes and trends for 17 different countries across major regions, globally.
By Type | |
Instruments | |
Assay Kits and Consumables |
By Diagnostic Technique | ||||
| ||||
Immunoassay-based Method | ||||
Mass Spectroscopy-based Method | ||||
Others |
By End User | |
Hospitals and Clinics | |
Diagnostic Laboratories | |
Others |
Geography | ||||||||
| ||||||||
| ||||||||
| ||||||||
| ||||||||
|
Global Virology Testing Market Size Summary
The virology testing market is poised for steady growth over the forecast period, driven by the ongoing impact of COVID-19 and the emergence of new viral strains. The pandemic has significantly influenced the market, with increased demand for diagnostic tests and kits to identify SARS-CoV-2 infections. This surge in demand has prompted market players to expand their product offerings, capitalizing on the need for effective diagnosis and screening. Collaborative efforts between industry stakeholders and government bodies, such as substantial investments in rapid testing solutions, have further bolstered market expansion. Additionally, the rising prevalence of viral diseases, including HIV, influenza, and Ebola, alongside the emergence of new pathogens, is expected to sustain the demand for virology testing. The market's growth is also supported by advancements in diagnostic techniques, particularly PCR-based methods, which have become integral in clinical and research settings due to their accuracy and efficiency in detecting viral pathogens.
Regionally, the virology testing market has experienced robust growth, particularly in the United States, attributed to the adoption of advanced diagnostic methods and increased healthcare spending. The presence of favorable government policies and advanced clinical laboratories has further propelled market expansion. The high incidence of viral infections, such as HIV, has driven demand for testing and diagnosis, contributing to market growth. The market is characterized by fragmentation, with several major players dominating the landscape. Companies like F. Hoffmann-La Roche AG, Bio-Rad Laboratories Inc., and Abbott Laboratories are key players, actively engaging in research and development to introduce innovative testing solutions. The introduction of novel tests, such as the Q-POC SARS-CoV-2, Flu A/B & RSV Assay, highlights the ongoing advancements in the field. Despite the promising growth prospects, the market faces challenges from stringent regulatory requirements regarding product approvals, which may impact the pace of market expansion.
Global Virology Testing Market Size - Table of Contents
-
1. MARKET DYNAMICS
-
1.1 Market Overview
-
1.2 Market Drivers
-
1.2.1 Surge in the Prevalence of Viral Diseases Worldwide
-
1.2.2 Increasing Product Approvals
-
-
1.3 Market Restraints
-
1.3.1 Stringent Regulations Regarding Product Development and Approvals
-
-
1.4 Porter's Five Force Analysis
-
1.4.1 Threat of New Entrants
-
1.4.2 Bargaining Power of Buyers/Consumers
-
1.4.3 Bargaining Power of Suppliers
-
1.4.4 Threat of Substitute Products
-
1.4.5 Intensity of Competitive Rivalry
-
-
-
2. MARKET SEGMENTATION
-
2.1 By Type
-
2.1.1 Instruments
-
2.1.2 Assay Kits and Consumables
-
-
2.2 By Diagnostic Technique
-
2.2.1 Molecular Diagnostics Method
-
2.2.1.1 PCR-based methods
-
2.2.1.2 NGS-based methods
-
-
2.2.2 Immunoassay-based Method
-
2.2.3 Mass Spectroscopy-based Method
-
2.2.4 Others
-
-
2.3 By End User
-
2.3.1 Hospitals and Clinics
-
2.3.2 Diagnostic Laboratories
-
2.3.3 Others
-
-
2.4 Geography
-
2.4.1 North America
-
2.4.1.1 United States
-
2.4.1.2 Canada
-
2.4.1.3 Mexico
-
-
2.4.2 Europe
-
2.4.2.1 Germany
-
2.4.2.2 United Kingdom
-
2.4.2.3 France
-
2.4.2.4 Italy
-
2.4.2.5 Spain
-
2.4.2.6 Rest of Europe
-
-
2.4.3 Asia-Pacific
-
2.4.3.1 China
-
2.4.3.2 Japan
-
2.4.3.3 India
-
2.4.3.4 Australia
-
2.4.3.5 South Korea
-
2.4.3.6 Rest of Asia-Pacific
-
-
2.4.4 Middle-East and Africa
-
2.4.4.1 GCC
-
2.4.4.2 South Africa
-
2.4.4.3 Rest of Middle-East and Africa
-
-
2.4.5 South America
-
2.4.5.1 Brazil
-
2.4.5.2 Argentina
-
2.4.5.3 Rest of South America
-
-
-
Global Virology Testing Market Size FAQs
How big is the Global Virology Testing Market?
The Global Virology Testing Market size is expected to reach USD 13.02 billion in 2024 and grow at a CAGR of 1.77% to reach USD 14.21 billion by 2029.
What is the current Global Virology Testing Market size?
In 2024, the Global Virology Testing Market size is expected to reach USD 13.02 billion.